Welcome to our Focus Edition on CAR T cell therapy news, which was presented at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, USA, from 11-14 December 2021. It was truly energising to be back at a medical conference, and ASH21 did not disappoint!The 3 phase 3 clinical trials reporting there about second-line use of CAR-T therapies for Diffuse Large B-Cell Lymphoma (DLBCL) were certainly one of the biggest stories to role out during the meeting. Two of the trials reported clear clinical benefit, but -surprisingly- the third one did not, which made for some extraordinary discussions.
Medicom’s Medical Science Officer, Dr Rachel Giles, went to ASH21 and interviewed a series of 7 experts presenting there about this topic, moderated a panel discussion of thought leaders in this field, was the editor for 10 accompanying articles you will find in this Focus, and generated a podcast on the topic as well. Read, watch, and/or listen to catch up on the latest news in CAR T-cell therapy in DLBCL!
Stay safe and stay healthy!
Posted on
Table of Contents: ASH 2021 Focus on CAR T-Cell Therapy
Featured articles
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
CAR T-cell Therapy
Most re-hospitalisations within first month from CAR T-cell infusion
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL
Improved QoL with axi-cel versus standard-of-care in R/R LBCL
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com